« The Lancet on Counterfeits | Main | Cell Culture »
May 20, 2008
Deal or No Deal
by Peter Pitts
According to a Bloomberg report, biotechnology acquisitions and licensing deals reached a record $27 billion worldwide last year. In the largest deal of the year, London-based AstraZeneca paid $15.6 billion to acquire MedImmune.
Biotechnology companies also raised $29.9 billion in investments and loans, the most since 2000. The industry attracted a record $39.4 billion in 2000, the year the first draft sequence of the human genome appeared.
IPOs brought in $2.2 billion, a 21 percent increase over the previous year and the highest total since 2000.
The full Bloomberg story can be found here:
http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a6FjDvLrCCgm
The article mentions that, “Large drugmakers are investing in biotechnology to gain new medicines to bolster revenue as patents on top products expire.”
No doubt. But while acquisitions and licensing is the wave of the present, what will drive the future of pipeline, profit … and public health is the Critical Path. To achieve “A” level health care, industry and academia and government must focus on “B” level issues -- Better science and better tools (biomarkers, bioinformatics, and Bayesian statistical analysis) among others.
So, deal or no deal, the Critical Path must not remain the road less traveled.
Posted by peterpitts at May 20, 2008 07:52 AM
Trackback Pings
TrackBack URL for this entry:
/cgi-bin/mt-tb.cgi/206
